Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jan 13, 2017 12:17pm
138 Views
Post# 25704663

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Time to get serious about this company

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Time to get serious about this companyToniv and GV,

Just to clarify, it doesn't matter if 0.4%, 0.6% or even something higher would have been achieved in ASSURE in the RVX-208 treated group if there is no statistically significant difference from the placebo group. The placebo group showed significant regression compared to the baseline placebo measures. The RVX-208-treated group showed significant regression compared to the basline RVX-208 measures. However, when comparing placebo to RVX-208, there was no significant difference between placebo and RVX-208 groups. ASSURE failed not because the RVX-208 group didn't a certain magnitude of regression. ASSURE failed because the trial failed to show any statistically significant benefit above and beyond placebo alone.

You two might have already known this....but I sensed some confusion and just wanted to clear that up just in case.

BearDownAZ
Bullboard Posts